Skip to main content

Table 2 Incidence rates of VTE among older RCC patients in the 12 months after cancer diagnosis

From: Older renal cell cancer patients experience increased rates of venous thromboembolic events: a retrospective cohort study of SEER-Medicare data

 

DVTa

PEa

OTEa

n = 11,950 RCC patients

N / P-Yb

Rate/1,000c(95% CI)

N / P-Yb

Rate/1,000c(95% CI)

N / P-Yb

Rate/1,000c(95% CI)

Age

      

  65-69

144/1,593

90.4 (76.2-106.4)

39/1,657

23.5 (16.7-32.2)

59/1,638

36.0 (27.4-46.5)

  70-74

306/2,883

106.2 (94.6-118.7)

84/3,011

27.9 (22.3-34.5)

170/2,965

57.4 (49.1-66.6)

  75-79

270/2,436

110.8 (98.0-124.4)

84/2,527

33.3 (26.5-41.2)

121/2,512

48.2 (40.0-57.6)

  80-84

175/1,479

118.3 (101.4-137.2)

60/1,546

38.8 (29.6-50.0)

75/1,539

48.7 (38.3-61.1)

  85+

95/759

125.2 (101.3-153.1)

19/795

23.9 (14.4-37.3)

37/781

47.4 (33.4-65.3)

Race

      

  Black

104/709

146.6 (119.8-177.1)

28/753

37.2 (24.7-53.8)

35/751

46.6 (32.4-64.8)

  White

838/7,908

106.0 (98.9-113.4)

248/8,227

30.1 (26.5-34.1)

405/8135

49.8 (45.1-54.9)

  Other

46/520

88.5 (64.8-188.1)

10/542

18.5 (8.9-34.0)

21/534

39.3 (24.3-60.1)

Sex

      

  Female

440/3,681

119.5 (108.6-131.2)

129/3,850

33.5 (28.0-39.8)

202/3,809

53.0 (46.0-60.9)

  Male

550/5,469

100.6 (92.3-109.3)

157/5,686

27.6 (23.5-32.3)

260/5,625

46.2 (40.8-52.2)

History of VTEd

      

  Yes

93/86

1086.7 (877.1-1,331.3)

24/25

974.3 (624.3-1,449.7)

37/77

482.8 (339.9-665.4)

  No

897/9,065

99.0 (92.6-105.7)

262/9,511

27.6 (24.3-31.1)

425/9,357

45.4 (41.2-50.0)

History of CVDe

      

  Yes

181/1,400

129.3 (111.1-149.5)

54/1,465

36.9 (27.7-48.1)

84/1,451

57.9 (46.2-71.7)

  No

809/7,750

104.4 (97.3-111.8)

232/8,071

28.7 (25.2-32.7)

378/7,983

47.4 (42.7-52.4)

Disease stage

      

  Localized

374/5,628

66.5 (59.9-73.5)

133/5,757

23.1 (19.3-27.4)

190/5,734

33.1 (28.6-38.2)

  Regional

290/1,749

165.8 (147.3-186.1)

62/1,899

32.7 (25.0-41.9)

154/1,837

83.9 (71.1-98.2)

  Distant

266/1,161

229.2 (202.5-258.5)

69/1,245

55.4 (43.1-70.2)

90/1,230

73.2 (58.8-89.9)

Immunotherapyf

      

  Yes

78/376

207.3 (163.8-258.6)

17/407

41.7 (24.3-66.8)

27/398

67.9 (44.7-98.7)

  No

912/8,774

103.9 (97.3-110.9)

269/9,128

29.5 (26.0-33.2)

435/9,036

48.1 (43.7-52.9)

Nephrectomy

      

  Yes

665/6,963

95.5 (88.4-103.1)

204/7,250

28.1 (24.4-32.3)

341/7,164

47.6 (42.7-52.9)

  No

325/2,188

148.6 (132.9-165.6)

82/2,286

35.9 (28.5-44.5)

121/2270

53.3 (44.2-63.7)

  1. aVTE = venous thromboembolic events; RCC = renal cell cancer; DVT = Deep Vein Thrombosis; PE = Pulmonary Embolism; OTE = Other thromboembolic event. OTE category includes the following diagnoses: central retinal vein occlusion, venous tributary (branch) occlusion, Nonpyogenic thrombosis of intracranial venous sinus, phlebitis/thrombophlebitis of superficial vessels of lower extremities, phlebitis/thrombophlebitis of superficial veins of upper extremities, phlebitis/thrombophlebitis of other sites, gout with other specified manifestations, Budd-Chiari syndrome, and venous embolism/thrombosis of renal vein.
  2. bN = number of VTE events; P-Y = person-years.
  3. cRates are per 1,000 person-years and are unadjusted. Age adjustment is unnecessary as these rates are intentionally representative of the older subpopulation (ages 65+) of RCC patients. Only first VTE counted in rate estimates.
  4. dHistory of VTE of interest in the 12 months before RCC diagnosis.
  5. eHistory of CVD is defined as a history of any of the following events in the 12 months before RCC diagnosis: myocardial infarction, ischemic stroke, onset congestive heart failure, angina, or TIA.
  6. fImmunotherapy in our data (1991–2003) predominantly included Interferon alpha and IL-2 therapies.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us